GlassScriptPhysician profile
Khoren Hekimian
NPI 1588695423
$12,432.79
in general payments reported to CMS, 2019-2025
34 companies · $6,339 in 2025
The $6,339 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $140 · 2021: $883 · 2022: $1,709 · 2023: $1,140 · 2024: $1,038 · 2025: $6,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,276 · Consulting Fee: $3,738 · Travel and Lodging: $493 · Education: $9.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,275.80 |
| Consulting Fee | $3,738.00 |
| Travel and Lodging | $493.07 |
| Education | $9.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $4,771.30 | 2025 | Yupelri |
| Neurocrine Biosciences, INC. | $1,409.98 | 2022-2025 | Ingrezza |
| Mylan Specialty L.P. | $864.60 | 2022-2024 | Yupelri, Yupelri |
| Avanir Pharmaceuticals, INC. | $764.30 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $677.58 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $557.43 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $555.66 | 2019-2025 | Nuplazid |
| Alpha Cognition USA, INC. | $527.95 | 2025 | Zunveyl |
| Ucb, INC. | $285.11 | 2019-2025 | Briviact |
| Astrazeneca Pharmaceuticals LP | $274.59 | 2021 | |
| Lundbeck LLC | $226.37 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $158.98 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $152.90 | 2023-2024 | Gemtesa, Aptiom |
| Lilly USA, LLC | $146.71 | 2021-2023 | Trulicity, Humalog, Baqsimi |
| Otsuka America Pharmaceutical, INC. | $143.45 | 2023-2025 | Rexulti, Nuedexta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $124.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $118.06 | 2019 | |
| Kyowa Kirin, INC. | $114.38 | 2021-2022 | |
| Alkermes, INC. | $99.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $91.58 | 2021-2022 | |
| Axsome Therapeutics, INC. | $63.65 | 2023-2025 | Auvelity |
| Biogen, INC. | $53.19 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.90 | 2021 | |
| Indivior INC. | $24.82 | 2023 | Perseris |
| Jazz Pharmaceuticals INC. | $24.38 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $21.63 | 2023 | Epkinly |
| Vivus LLC | $21.43 | 2022 | |
| Almatica Pharma LLC | $18.89 | 2024 | Loreev Xr |
| Aimmune Therapeutics, INC. | $17.77 | 2024 | |
| Eisai INC. | $17.67 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.09 | 2024 | Rytary |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.08 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $15.08 | 2024 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khoren Hekimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.